Stockreport

Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Adverum Biotechnologies, Inc.  (ADVM) 
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: adverum.gcs-web.com/investor-overview
PDF Patients in Cohort 4 of OPTIC will Receive a Single ADVM-022 Dose of 6 x 10 ^11 vg/eye REDWOOD CITY, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologie [Read more]